Sub-Tenon’s capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation
Sign Up to like & getrecommendations! Published in 2022 at "Graefe's Archive for Clinical and Experimental Ophthalmology"
DOI: 10.1007/s00417-022-05611-y
Abstract: To investigate the efficacy of sub-Tenon’s capsule triamcinolone acetonide (STTA) injections for preventing development of intraocular inflammation (IOI) related to intravitreal injection (IVI) of brolucizumab for neovascular age-related macular degeneration (nAMD). Consecutive patients with nAMD… read more here.
Keywords: brolucizumab; capsule triamcinolone; tenon capsule; injection ... See more keywords
Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab
Sign Up to like & getrecommendations! Published in 2022 at "Graefe's Archive for Clinical and Experimental Ophthalmology"
DOI: 10.1007/s00417-022-05634-5
Abstract: Treatment of choroidal neovascularization due to age-related macular degeneration is a challenging topic since an increasing number of patients show reduced morphological response to conventional treatment with intravitreal injections. The present study tested the hypothesis… read more here.
Keywords: brolucizumab; pre treated; treated patients; treatment ... See more keywords
Three Japanese cases of intraocular inflammation after intravitreal brolucizumab injections in one clinic
Sign Up to like & getrecommendations! Published in 2021 at "Japanese Journal of Ophthalmology"
DOI: 10.1007/s10384-021-00819-7
Abstract: To report the development of intraocular inflammation (IOI) in three Japanese patients in the same clinic after intravitreal injections (IVI) of brolucizumab to treat neovascular age-related macular degeneration. The major findings were: (1) all three… read more here.
Keywords: cases intraocular; brolucizumab; three japanese; japanese cases ... See more keywords
Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Sign Up to like & getrecommendations! Published in 2017 at "Ophthalmology"
DOI: 10.1016/j.ophtha.2017.03.057
Abstract: PURPOSE To compare the efficacy and safety of brolucizumab with aflibercept to treat neovascular age-related macular degeneration (AMD). DESIGN Prospective, randomized, double-masked, multicenter, 2-arm, phase 2 study. PARTICIPANTS Eighty-nine treatment-naïve participants, aged ≥50 years, with… read more here.
Keywords: week; brolucizumab; treatment; versus aflibercept ... See more keywords
Brolucizumab—another anti-VEGF or beyond
Sign Up to like & getrecommendations! Published in 2020 at "Eye"
DOI: 10.1038/s41433-020-0888-y
Abstract: There are quite a few anti-VEGFs that are used in ophthalmic practice to treat a variety of conditions. Ranibizumab {(Lucentis; Genentech, South San Francisco, CA) (Razumab; Intas Pharmaceutical Ltd, Ahmedabad, India * Biosimilar of ranibizumab… read more here.
Keywords: anti vegf; vegf; brolucizumab; antibody ... See more keywords
A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE).
Sign Up to like & getrecommendations! Published in 2020 at "Klinische Monatsblatter fur Augenheilkunde"
DOI: 10.1055/a-1101-9126
Abstract: BACKGROUND Brolucizumab is a single-chain variable antibody fragment (scVF) that specifically binds to VEGF-A. The results of two large phase III, multicentre, randomized clinical trials comparing intravitreal treatment with Brolucizumab and Aflibercept in neovascular age-related… read more here.
Keywords: phase; brolucizumab; treatment; study ... See more keywords
Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD
Sign Up to like & getrecommendations! Published in 2021 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2021.1915278
Abstract: ABSTRACT Introduction Wet age-related macular degeneration (w-AMD) represents the leading cause of visual impairment in the elderly in the developed countries. Intravitreal antivascular endothelial growth factor (VEGF) drugs are currently considered as the first-line treatment… read more here.
Keywords: treating amd; brolucizumab; anti vegf; novel anti ... See more keywords
SHORT-TERM OUTCOMES AFTER INTERIM TREATMENT WITH BROLUCIZUMAB
Sign Up to like & getrecommendations! Published in 2022 at "Retina"
DOI: 10.1097/iae.0000000000003418
Abstract: Short-term brolucizumab therapy may result in anatomical benefits that are maintained for at least 6 months after switching to an alternative anti–vascular endothelial growth factor treatment while minimizing the risk of brolucizumab-related intraocular inflammation. Purpose:… read more here.
Keywords: treatment brolucizumab; brolucizumab; eyes decreased; interim treatment ... See more keywords
Brolucizumab for the treatment of diabetic macular edema.
Sign Up to like & getrecommendations! Published in 2022 at "Current opinion in ophthalmology"
DOI: 10.1097/icu.0000000000000849
Abstract: PURPOSE OF REVIEW To review the available data supporting the use of brolucizumab in the treatment of diabetic macular edema (DME). RECENT FINDINGS Brolucizumab is a humanized single- chain variable antibody fragment (scFv), the smallest… read more here.
Keywords: brolucizumab; macular edema; brolucizumab treatment; treatment ... See more keywords
Efficacy and safety of brolucizumab in age‐related macular degeneration: A systematic review of real‐world studies
Sign Up to like & getrecommendations! Published in 2022 at "Acta Ophthalmologica"
DOI: 10.1111/aos.15242
Abstract: Intravitreally injected anti‐vascular endothelial growth factor (anti‐VEGF) agents are first‐line treatment for neovascular age‐related macular degeneration (nAMD). Phase 3 trials demonstrated non‐inferiority of anti‐VEGF therapy with brolucizumab compared with aflibercept in best corrected visual acuity… read more here.
Keywords: efficacy safety; treatment; real world; brolucizumab ... See more keywords
A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab
Sign Up to like & getrecommendations! Published in 2023 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abq5068
Abstract: Immunogenicity against intravitreally administered brolucizumab has been previously described and associated with cases of severe intraocular inflammation, including retinal vasculitis/retinal vascular occlusion (RV/RO). The presence of antidrug antibodies (ADAs) in these patients led to the… read more here.
Keywords: pharmacology; immune complexes; immunogenicity; mechanistic drivers ... See more keywords